Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07261163CT.gov Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT07460362CT.gov Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06504199CT.gov Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT06192888CT.gov A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05910801CT.gov Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT05861050CT.gov Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT05788289CT.gov A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT05564052CT.gov A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT04635683CT.gov Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT05992597CT.gov ZR2 Sequential Immunochemotherapy for Newly Treated MCL | — | Recruiting | — | — | — |
Show 29 more trialsShow fewer
NCT05025800CT.gov ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05076097CT.gov A Study of OLR in First-line Treatment of Mantle Cell Lymphoma | — | Unknown | — | — | — |
NCT04578600CT.gov CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | — | Completed | — | — | — |
NCT04036448CT.gov A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea | — | Completed | — | — | — |
NCT03863184CT.gov Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | — | Active Not Recruiting | — | — | — |
NCT03891355CT.gov Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL | — | Unknown | — | — | — |
NCT04047797CT.gov Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT03232307CT.gov Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT03856112CT.gov Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03523975CT.gov Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT03616782CT.gov Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | — | Unknown | — | — | — |
NCT03323151CT.gov A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03019640CT.gov Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT02568553CT.gov Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02281279CT.gov Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | — | Withdrawn | — | — | — |
NCT02632396CT.gov Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | — | Unknown | — | — | — |
NCT02633137CT.gov Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT02446236CT.gov Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02460276CT.gov A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT01865110CT.gov R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | — | Completed | — | — | — |
NCT01838434CT.gov Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT01955499CT.gov Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01744912CT.gov Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | — | Terminated | — | — | — |
NCT01737177CT.gov Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL | — | Completed | — | — | — |
NCT01075321CT.gov Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01116154CT.gov Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT01088048CT.gov Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia | — | Completed | — | — | — |
NCT00963534CT.gov Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. | — | Completed | — | — | — |
NCT00786851CT.gov Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mantle Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lenalidomide (this asset) | Institute of Hematology & Blood Diseases Hospital, China | P3 | B · 62 |
| Etoposide | Ruijin Hospital | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Irinotecan | University of Michigan Rogel Cancer Center | P2 | BBB |
| Busulfanum | City of Hope Medical Center | P2 | BBB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Cediranib | City of Hope Medical Center | P2 | BB |
+42 more in the Mantle Cell Lymphoma cohort
Other indications for Lenalidomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 74 |
| Plasma Cell Neoplasm | — | P3 | BBB · 72 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lenalidomide in Mantle Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lenalidomide-mantle-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →